Ongoing Pharma-Initiated Clinical Trials

2021

Plegridy observational program (POP study)

2021

Safety, tolerability and effectiveness of ofatumumab in patients with relapsing MS (ALITHIOS study)

2021

Ocrelizumab treatment of relapsing MS (CASTING/LIBERTO study)

2021

Ocrelizumab treatment of progressive MS (CONSONANCE study)

2021

Dimethyl fumarate observational study (ESTEEM study)

2021

Quality of life in patients with highly active relapsing MS (CLARIFY MS study)

2021

Effectiveness and safety of ocrelizumab in patients with early stage relapsing MS (ENSEMBLE study)

2021

Efficacy and safety of fenebrutinib in patients with primary progressive MS (FENtrepid study)

Completed Pharma-Initiated Clinical Trials

The year refers to the date of publication (PubMed) or latest update on ClinicalTrial.gov

2020

The efficacy and safety of ponesimod (POINT study)

2020

Ofatumumab versus teriflunomide in relapsing MS (ASCLEPIOS I study)

2020

Efficacy and safety of dimethyl fumarate in pediatric patients with relapsning MS (CONNECT study)

2020

Safety of fingolimode in patients with MS

2019

Long-term extension study to evaluate safety and efficacy of daclizumab (EXTEND study)

2019

Vitamin D3 as an add on to IFN-beta 1-alpha in treatment of relapsing MS (SOLAR study)

2018

Natalizumab treatment of secondary progressive MS (ASCEND study)

2018

Subcutaneous IFN-beta 1-alpha treatment of relapsing MS (ScanSmart study)

2018

Subcutaneous ofatumumab treatment of relapsing MS (MIRROR study)

2017

Long-term follow up of fingolimod in relapsing MS (ACROSS study)

2017

Optical coherence tomography in relapsing MS (OCTIMS study)

2017

Ocrelizumab treatment of primary progressive MS (ORATORIO study)

2016

Oral fingolimod in primary progressive MS (INFORMS study)

2016

Natalizumab re-initiation of dosing (STRATA study)

2015

Observational study of subcutaneous IFN-beta 1-alpha treatment of relapsing MS (SMART study)

2015

Daclizumab versus IFN-beta 1-alpha treatment of relapsing MS (DECIDE study)

2014

Efficacy and safety of teriflunomide in patients with relapsing MS (TERACLES study)

2014

Observational study of patients with relapsing MS converting to glatiramer acetate (COPTIMIZE study)

2014

Efficacy of converting to natalizumab in treatment of active MS (SURPASS study)

2013

Safety and efficacy of autologous mesenchymal stem cell treatment of active MS (MESEMS study)

2012

Firategrast treatment of relapsing MS

2011

Subcutanous IFN-beta 1-alpha in patients with a first clinical demyelinating event (REFLEX study)

2011

Teriflunomide treatment of relapsing MS (TEMSO study)

2011

Efficacy and safety of MBP8298 treatment of secondary progressive MS (MAESTRO study)

2010

Cladribine treatment of relapsing MS (CLARIFY study)

2009

Effect of glatiramer acetate on conversion to clinically definite MS (PreCISe study)

2009

Fingolimod treatment of relapsing MS

2009

Fatique outcome in copaxone users (FOCUS study)

2007

IVIG in postpartum relapsing MS (GAMPP study)

2007

Combination therapy of natalizumab and IFN-beta 1-alpha in relapsing MS (SENTINEL study)

2007

3-year follow up of the BENEFIT study (BENEFIT extension study)

2006

Natlizumab treatment of relapsing MS (AFFIRM study)

2006

IFN-beta 1-beta treatment of patients with CIS (BENEFIT study)

2006

Glatiramer acetate treatment of relapsing MS (CORAL study)

2006

Early treatment of MS with IFN-beta 1-alpha (ETOMS study)

2005

IV immunoglobulin treatment in acute opticus neuritis

2004

Intravenous immunoglobulin in secondary progressive MS (ESIMS study)

2001

Liver and thyroid function and autoimmunity during IFN-beta 1-beta treatment (BEST study)

2001

IFN-beta 1-alpha treatment of secondary progressive MS (SPECTRIMS study)

2000

Linomide in the treatment of MS